NeoPharm: more promising survival data for cintredekin besudotox

June 2006
PharmaWatch: Biotechnology;Jun2006, Vol. 5 Issue 6, p5
Market Research Report
The article reports on NeoPharm Inc.'s release of the results of phase I/II clinical trial of hts cintredekin besudotox. The updated data showed that the overall median survival of the 45 patients with glioblastoma multiforme (GBM) was 44 weeks. Long-term follow-up demonstrated 22 patients with GMB had a median survival of more than one year.


Related Articles

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Cancer;Jun2006, Vol. 5 Issue 6, p11 

    The article reports on NeoPharm's release of update phase I/II data for cintredekin besudotox that shows increased survival in glioblastoma multiforme patients. The drug is a chimeric interleukin-13 conjugated to a genetically engineered Pseudomonas exotoxin. The phase III trial was initiated in...

  • FDA Wants Another Phase III For NeoPharm's GBM Drug. Morrison, Trista // BioWorld Today;3/30/2007, Vol. 18 Issue 62, p2 

    The author reports on the demand by the U.S. Food and Drug Administration (FDA) Office of Oncology for another phase III trial of cintredekin besudotox, before granting approval for its use in the treatment of recurrent glioblastoma multiforme. The drug failed to meet its primary endpoint in a...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma...

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Monthly Review;Jun2006, Vol. 5 Issue 6, p7 

    The article comments on the results of the phase I/II trial on the survival, drug safety and quality of life for glioblastoma multiforme (GM) patients receiving NeoPharm's cintredekin besudotox (CB). The data showed that the overall median survival of the patients with GM was 44 weeks. CB or IL...

  • In spite of criticism, Lilly saves lives. Schenck, Steven J. // Indianapolis Business Journal;3/30/2009, Vol. 30 Issue 4, p11A 

    The author shares his views on the success of Indianapolis, Indiana-based drug company Eli Lilly & Co. in introducing the trial drug Enzastaurin, which has saved the life of his wife. He narrates how his wife suffering from glioblastoma was cured by a clinical trial using the drug. The author...

  • The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review. Badruddoja, Michael A.; Elquza, Emad; Welsh, James; Cooke, Laurence; Sanan, Abhay; Stea, Baldassrre; Mahadavan, Daruka // Letters in Drug Design & Discovery;May2010, Vol. 7 Issue 4, p290 

    The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB...

  • Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue.  // Biomedical Market Newsletter;6/30/2011, p279 

    The article reports on the positive interim results from Parsippany, New Jersey-based Arno Therapeutics Inc.'s Glioblastoma Phase II clinical study of AR-67 camptothecin for patients with glioblastoma multiforme (GBM) who were not treated with Avastin. It states that the study is designed to...

  • CLINIC ROUNDUP.  // BioWorld Today;9/29/2008, Vol. 19 Issue 189, p2 

    This section offers news briefs on the pharmaceutical industry in North America. A Phase I study has been completed by Memory Pharmaceuticals Corp. involving its R4996/MEM 63908. Meanwhile, Thallion Pharmaceuticals Inc. has enrolled the first patient in its Phase II trial of TLN-4601 as a...

  • NeoPharm colorectal cancer drug misses target.  // PharmaWatch: Cancer;May2007, Vol. 6 Issue 5, p16 

    The article reports on the announcement of biopharmaceutical company NeoPharm Inc. on the failure of its phase II trial in second-line metastatic colorectal cancer patients with its product LESN38 to produce the desired results. While the interim analysis of data following the completion of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics